JPRN-UMIN000011562招募中未知
Efficacy and safety of everolimus (Certican) plus once-daily prolonged-release tacrolimus (Graceptor) combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial. - Efficacy and safety of everolimus plus once-daily prolonged-release tacrolimus combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial.
Tokyo Women's Medical University, Dep. Urology0 个研究点目标入组 120 人开始时间: 2013年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Inability or un willingness to sign a consent form. 2. Subject under 20 years old. 3.ABO blood incompatible kidney transplantation 4.Unable to outpatient treatment in study period 5.Pregnancy or possible to pregnant 6.Serious digestive disease 7.Active infectious disease 8. Cancer 9. Hypersensibility to sirolimus or everolimus 10. Investigator considered inappropriate as a subject of this study.
研究者
相似试验
进行中（未招募）
1 期
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)EUCTR2012-004550-28-DEAIO-Studien-gGmbH
已完成
4 期
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant RecipientsChronic Renal FailureNCT00965094Novartis Pharmaceuticals36
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-CZovartis Pharma AG490
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIEUCTR2004-002267-24-HUovartis Pharma AG384
进行中（未招募）
不适用
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-ESovartis Pharma AG483